Aquestive Therapeutics, Inc.

NasdaqGM:AQST Stock Report

Market Cap: US$285.4m

Aquestive Therapeutics Management

Management criteria checks 1/4

Aquestive Therapeutics' CEO is Dan Barber, appointed in May 2022, has a tenure of 2.67 years. total yearly compensation is $2.50M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 1.52% of the company’s shares, worth $4.33M. The average tenure of the management team and the board of directors is 2.2 years and 2.4 years respectively.

Key information

Dan Barber

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage24.0%
CEO tenure2.7yrs
CEO ownership1.5%
Management average tenure2.2yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Aquestive Therapeutics: Five Foci For 2025

Jan 06

The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%

Dec 19
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 05

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

CEO Compensation Analysis

How has Dan Barber's remuneration changed compared to Aquestive Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Sep 30 2019n/an/a

-US$68m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$80m

Dec 31 2018US$2mUS$319k

-US$61m

Compensation vs Market: Dan's total compensation ($USD2.50M) is above average for companies of similar size in the US market ($USD1.41M).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Barber (48 yo)

2.7yrs

Tenure

US$2,496,141

Compensation

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Barber
CEO, President & Director2.7yrsUS$2.50m1.52%
$ 4.3m
A. Toth
Chief Financial Officer4.1yrsUS$1.12m0.43%
$ 1.2m
Lori Braender
Chief Legal Officer6.3yrsUS$1.19m0.52%
$ 1.5m
Cassie Jung
Chief Operating Officer2.2yrsno data0.25%
$ 712.3k
Stephen Wargacki
Chief Science Officerno datano data0.28%
$ 807.4k
Sherry Korczynski
Senior Vice President of Sales & Marketingless than a yearno data0.027%
$ 78.3k
Peter Boyd
Senior Vice President of Information Technology & Human Resources1.8yrsno data0.26%
$ 743.8k
Gary Slatko
Chief Medical Officerno datano datano data
Carl Kraus
Chief Medical Officer1.6yrsno data0.28%
$ 787.8k
Robert Arnold
VP of Financeno datano datano data

2.2yrs

Average Tenure

56yo

Average Age

Experienced Management: AQST's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Barber
CEO, President & Director2.7yrsUS$2.50m1.52%
$ 4.3m
Timothy Morris
Independent Director2.4yrsUS$145.23k0%
$ 0
Gregory Brown
Independent Chairman of the Board17.8yrsUS$150.77k0.082%
$ 235.0k
Julie Krop
Independent Director3.9yrsUS$137.69k0%
$ 0
John Cochran
Independent Vice Chairman of the Board21yrsUS$137.23k0.11%
$ 311.4k
Marco Taglietti
Independent Director3.9yrsUS$121.78k0%
$ 0
Carlos Camargo
Member of Scientific Advisory Board2.3yrsno datano data
Ruchi Gupta
Member of Scientific Advisory Board2.3yrsno datano data
David Bernstein
Member of Scientific Advisory Board2.3yrsno datano data
David Fleischer
Member of Scientific Advisory Board2.3yrsno datano data
Matthew Greenhawt
Member of Scientific Advisory Board2.3yrsno datano data
Jay Lieberman
Member of Scientific Advisory Board2.3yrsno datano data

2.4yrs

Average Tenure

60.5yo

Average Age

Experienced Board: AQST's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:01
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aquestive Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Gary NachmanBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.